BioXcel Therapeutics (BTAI) announced that the FDA has accepted its supplemental new drug application, or sNDA, for approval of Igalmi for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia. The FDA has assigned a Prescription Drug User Fee Act target action date of November 14.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI:
- Morning Movers: AstraZeneca jumps following tozorakimab trial results
- BioXcel Therapeutics reports Q4 EPS (58c), consensus (63c)
- BioXcel Therapeutics initiated with a Buy at Rodman & Renshaw
- BioXcel Therapeutics Announces Registered Direct Equity Financing
- BioXcel price target lowered to $6 from $10 at H.C. Wainwright